(E)-1-(4-methoxyphenylsulfonyl)-4-phenyl-2,3,6,7-tetrahydro-1H-azepine | 1116680-15-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-1-(4-methoxyphenylsulfonyl)-4-phenyl-2,3,6,7-tetrahydro-1H-azepine
• 英文别名: 1-(4-methoxyphenyl)sulfonyl-4-phenyl-2,3,6,7-tetrahydroazepine
• CAS: 1116680-15-9
• 化学式: C₁₉H₂₁NO₃S
• 分子量: 343.447
• InChiKey: IZVJVOFBODYIPK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-苯基-氮杂环庚烷-4-醇 、 对甲氧基苯磺酰氯 在 盐酸 、 溶剂黄146 、 N,N-二异丙基乙胺 作用下， 以 水 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 (E)-1-(4-methoxyphenylsulfonyl)-5-phenyl-2,3,4,7-tetrahydro-1H-azepine 、 (E)-1-(4-methoxyphenylsulfonyl)-4-phenyl-2,3,6,7-tetrahydro-1H-azepine
  参考文献：
  名称：

  The discovery of azepane sulfonamides as potent 11β-HSD1 inhibitors

  摘要：

  Discovery of a series of azepine sulfonamides as potent inhibitors of 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) is described. SAR studies at the 4-position of the azepane ring have resulted in the discovery of a very potent compound 30 which has an 11 beta-HSD1 IC50 of 3.0 nM. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.07.003

文献信息

• [EN] SUBSTITUTED AZEPINE- AND DIAZEPINE-SULFONAMIDES USEFUL TO INHIBIT 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1<br/>[FR] SULFONAMIDES À SUBSTITUTION AZÉPINE ET DIAZÉPINE UTILISÉS POUR INHIBER LA 11-BÊTA-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE DE TYPE-1
  申请人：SCHERING CORP

  公开号：WO2009023664A3

  公开（公告）日：2009-07-23
• SUBSTITUTED AZEPINE-SULFONAMIDES USEFUL TO INHIBIT 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2190820B1

  公开（公告）日：2013-04-10
• SUBSTITUTED AZEPINE- AND DIAZEPINE-SULFONAMIDES USEFUL TO INHIBIT 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1
  申请人：Neelamkavil Santhosh

  公开号：US20110129542A1

  公开（公告）日：2011-06-02

  In its many embodiments, the present invention relates to a novel class of substituted azepine- and diazepine-sulfonamide compounds useful to inhibit 11β-hydroxysteroid dehydrogenase type-I, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the expression of 11β-hydroxysteroid dehydrogenase type-I using such compounds or pharmaceutical compositions.